The success of Sildenafil initially drove a boom for the drug industry, but recent developments present a murky outlook for shareholders. Lower-cost versions are eating into earnings, and ongoing patent challenges add more complexity to the landscape. While specific companies could still benefit from related offerings, the general trend suggests… Read More